USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: MICROBIOTIX, INC
City: WORCESTER
State: MA
Zip+4: -
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Website URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $17,408,694.00 34
SBIR Phase II $18,639,995.00 8
STTR Phase I $2,713,534.00 4

Award List:

BACTERIAL DNA POLYMERASES: TARGETS FOR NOVEL ANTIBIOTIC

Award Year / Program / Phase: 2001 / SBIR / Phase I
Agency: HHS
Principal Investigator: Michelle M. Butler
Award Amount: $224,291.00
Abstract:
DESCRIPTION (Applicant's abstract): The objective of this project is to identify novel drugs to treat antibiotic-resistant Gr+ and Gr- bacterial infections. The work will utilize an unexploited target, the class III bacterial DNA polymerase (pol III). The… More

A NOVEL THERAPY FOR RESPIRATORY SYNCYTIAL VIRUS

Award Year / Program / Phase: 2003 / SBIR / Phase I
Agency: HHS
Principal Investigator: Michelle M. Butler
Award Amount: $398,997.00
Abstract:
DESCRIPTION (provided by applicant): There is a clinical need for a cost-effective, non-toxic oral therapy to treat Respiratory Syncytial Virus (RSV) infections in young children and immuno ompromised adults. Microbiotix is developing NMSO3, a readily soluble sodium salt of a sulfated sialic… More

A POTENT ORAL THERAPY FOR CYTOMEGALOVIRUS INFECTION

Award Year / Program / Phase: 2003 / SBIR / Phase I
Agency: HHS
Principal Investigator: Terry L. Bowlin
Award Amount: $303,697.00
Abstract:
DESCRIPTION (provided by applicant): Cytomegalovirus infection represents a major health concern in the immunocompromised population, causing a variety of serious and even life threatening disorders. The current standard of care for CMV infection, ganciclovir, suffers from complications of low… More

NMSO3: A NOVEL THERAPY FOR RESPIRATORY SYNCYTIAL VIRUS

Award Year / Program / Phase: 2004 / SBIR / Phase II
Agency: HHS
Principal Investigator: Terry L. Bowlin
Award Amount: $1,476,106.00
Abstract:
DESCRIPTION (provided by applicant): There is a clinical need for a new cost-effective, non-toxic therapy to treat Respiratory Syncytial Virus (RSV) infections in young children and immunocompromised adults. Microbiotix, Inc. is developing NMSO3 as a treatment, intranasal delivery, for RSV… More

Novel Therapies for BioFilm-Related Infections

Award Year / Program / Phase: 2004 / SBIR / Phase II
Agency: HHS
Principal Investigator: Timothy J. Opperman
Award Amount: $1,443,595.00
Abstract:
DESCRIPTION (provided by investigator): Biofilms are surface attached bacterial communities encased in a hydrated matrix of exopolysaccharide. In the body, infecting bacteria form biofilms on medical implants, such as indwelling catheters. In this biofilm mode of growth, they are resistant to… More

BACTERIAL DNA POLYMERASES: TARGET FOR NOVEL ANTIBIOTICS

Award Year / Program / Phase: 2004 / SBIR / Phase I
Agency: HHS
Principal Investigator: Michelle M. Butler
Award Amount: $0.00
Abstract:
DESCRIPTION (provided by applicant): The results of a Phase I SBIR have provided a novel class of inhibitors active against gram-positive (Gr+) bacteria and against DNA polymerase (pol) IIIC and E. This is an ideal scaffold upon which to build a Structure Activity Relationship (SAR) and optimum… More

BACTERIAL DNA POLYMERASES: TARGET FOR NOVEL ANTIBIOTICS

Award Year / Program / Phase: 2004 / SBIR / Phase II
Agency: HHS
Principal Investigator: Michelle M. Butler
Award Amount: $1,369,504.00
Abstract:
DESCRIPTION (provided by applicant): The results of a Phase I SBIR have provided a novel class of inhibitors active against gram-positive (Gr+) bacteria and against DNA polymerase (pol) IIIC and E. This is an ideal scaffold upon which to build a Structure Activity Relationship (SAR) and optimum… More

BACTERIAL DNA HELICASES: TARGETS FOR NOVEL ANTIBIOTICS

Award Year / Program / Phase: 2005 / SBIR / Phase I
Agency: HHS
Principal Investigator: Marjorie H. Barnes
Award Amount: $260,831.00
Abstract:
DESCRIPTION (provided by applicant): We intend to develop new chemical classes of antibacterials by focusing on an under-exploited target in a well-validated pathway. Specifically, we will develop and apply a high throughput screen for inhibitors of the Staphylococcus aureus replicative DNA… More

THERAPEUTIC APPROACHES TO BIOFILM ANTIBIOTIC RESISTANCE

Award Year / Program / Phase: 2005 / SBIR / Phase I
Agency: HHS
Principal Investigator: Timothy J. Opperman
Award Amount: $304,821.00
Abstract:
DESCRIPTION (provided by applicant): Staphylococcus epidermidis and Staphylococcus aureus are the leading causes of indwelling-device related infections, affecting up to 400,000 patients/year in the United States. In the body, these pathogens form biofilms on medical implants that are intrinsically… More

Small Molecule Inhibitors of Anthrax Lethal Factor

Award Year / Program / Phase: 2005 / SBIR / Phase I
Agency: HHS
Principal Investigator: Norton P. Peet
Award Amount: $1,437,927.00
Abstract:
DESCRIPTION (provided by applicant): Aerosolized spores of Bacillus anthracis represent one of the most serious bio-terrorist threats to the security of the United States. New therapeutics based upon novel chemical scaffolds are vital to the biodefense armory because they are likely to be effective… More

DEVELOPMENT OF SCREENS FOR BACILLUS ANTHRACIS TARGETS

Award Year / Program / Phase: 2005 / SBIR / Phase I
Agency: HHS
Principal Investigator: Michelle M. Butler
Award Amount: $386,681.00
Abstract:
DESCRIPTION (provided by applicant): New antibiotics based on novel chemical scaffolds are vital to the biodefense armory primarily because they will be effective against both natural and engineered resistant forms of bioterrorist microbes. In addition, the absence of a reservoir of pre-existing… More

DNA helicase and primase inhibitors for biodefense

Award Year / Program / Phase: 2005 / STTR / Phase I
Agency: HHS
Research Institution: UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY
Principal Investigator: Donald T. Moir
Award Amount: $1,146,527.00
RI Contact: N/A
Abstract:
DESCRIPTION (provided by applicant): The long-term goal of this project is to identify specific inhibitors of B. anthracis helicase and primase and develop them into novel antibiotics for bio-defense. New antibiotics based on novel chemical scaffolds are vital to the bio-defense armory because they… More

Discovery of B. pseudomallei therapeutics for Biodefense

Award Year / Program / Phase: 2006 / SBIR / Phase II
Agency: HHS
Principal Investigator: Donald T. Moir
Award Amount: $3,214,170.00
Abstract:
DESCRIPTION (provided by applicant): Burkholderia pseudomallei is a bioterrorist threat. With the best current therapies, lethality is typically as high as 40%. The overall goal of this proposal is the development of new drugs against this organism. In Phase I, the high sequence similarity between… More

Type III Secretion Inhibitors for Anti-Infective Therapy

Award Year / Program / Phase: 2006 / SBIR / Phase I
Agency: HHS
Principal Investigator: Donald T. Moir
Award Amount: $653,644.00
Abstract:
DESCRIPTION (provided by applicant): Pseudomonas aeruginosa is a common and extremely virulent cause of serious infections in immune- compromised/suppressed patients (e.g., HIV and cancer), cystic fibrosis patients, and those on mechanical ventilation or with burn wounds. Frequent antibiotic… More

Identification of HCV E1 an E2 Inhibitors

Award Year / Program / Phase: 2006 / SBIR / Phase I
Agency: HHS
Principal Investigator: Arnab Basu
Award Amount: $371,054.00
Abstract:
DESCRIPTION (provided by applicant): Hepatitis C Virus (HCV) is recognized as a worldwide health problem affecting over 170 million people. HCV causes a spectrum of disease ranging from an asymptomatic carrier state to end-stage liver disease; which includes cirrhosis and hepatocellular carcinoma. A… More

Identification of Ebola Virus Entry Inhibitors

Award Year / Program / Phase: 2006 / SBIR / Phase I
Agency: HHS
Principal Investigator: Arnab Basu
Award Amount: $720,449.00
Abstract:
DESCRIPTION (provided by applicant): Ebola virus (EBOV) causes periodic outbreaks of severe viral hemorrhagic fevers in Africa with high mortality rates in infected patients. EBOV can be used in acts of bio-terrorism because of its highly infectious nature and stability in aerosolized form. It is… More

DEVELOPMENT OF INHIBITORS OF MYCOBACTERIUM TUBERCULOSIS DNA REPLICATION

Award Year / Program / Phase: 2006 / SBIR / Phase I
Agency: HHS
Principal Investigator: Michelle M. Butler
Award Amount: $514,896.00
Abstract:
DESCRIPTION (provided by applicant): New antibiotics based on novel chemical scaffolds against new bacterial targets are vital to reducing the tide of tuberculosis (TB) infection worldwide. Due to the lengthy treatment requirements and the difficulty in achieving treatment compliance, there is an… More

c-diGMP Signal Transduction Proteins are Biofilm Drug Targets

Award Year / Program / Phase: 2006 / SBIR / Phase I
Agency: HHS
Principal Investigator: Timothy J. Opperman
Award Amount: $367,815.00
Abstract:
DESCRIPTION (provided by applicant): Cystic Fibrosis (CF) is a genetic disorder that affects the major airways of the lungs of more than 30,000 people in the United States. The altered airways of 80% of CF patients are afflicted with a persistent bacterial colonization by Pseudomonas aeruginosa.… More

Novel Inhibitors of Staphylococcal Biofilm Formation

Award Year / Program / Phase: 2007 / SBIR / Phase I
Agency: HHS
Principal Investigator: John D. Williams
Award Amount: $493,342.00
Abstract:
DESCRIPTION (provided by applicant): Biofilm-related infections caused by Staphylococcus epidermidis and Staphylococcus aureus pose significant medical challenges. They are the leading cause of hospital-acquired infections, affecting up to 400,000 patients /year in the United States. In order to… More

TLR5 Antagonists for Infectious Disease Therapy

Award Year / Program / Phase: 2007 / STTR / Phase I
Agency: HHS
Research Institution: HARVARD MEDICAL SCHOOL
Principal Investigator: Stephen Lory
Award Amount: $597,858.00
RI Contact: N/A
Abstract:
DESCRIPTION (provided by applicant): A family of conserved toll-like receptors (TLRs) found on a variety of human cell types plays an important role in recognition of invading pathogens and in mounting an effective inflammatory immune response. Each these receptors binds a specific microbial ligand… More

Inhibition of Ebola Virus Infection with Cathepsin L Inhibitors

Award Year / Program / Phase: 2007 / SBIR / Phase I
Agency: HHS
Principal Investigator: Norton P. Peet
Award Amount: $600,000.00
Abstract:
DESCRIPTION (provided by applicant): Ebola virus is one of the most lethal infectious threats to mankind. These infections cause severe hemorrhagic fevers in humans and non-human primates and produce mortality rates of up to 90%. Ebola virus is classified in the NIAID Biodefense Research Agenda for… More

Quinoline-Based Inhibitors of Botulinum Neurotoxin A

Award Year / Program / Phase: 2007 / SBIR / Phase I
Agency: HHS
Principal Investigator: Norton P. Peet
Award Amount: $588,436.00
Abstract:
DESCRIPTION (provided by applicant): The botulinum neurotoxins (BoNTs) represent a group of the most poisonous biological substances known (1- 3). Seven different serotypes of BoNTs (BoNT/A through BoNT/G) are secreted by the anaerobic spore- forming bacte ria Clostridium botulinum, Clostridium… More

A POTENT ORAL THERAPY FOR CYTOMEGALOVIRUS INFECTION

Award Year / Program / Phase: 2008 / SBIR / Phase II
Agency: HHS
Principal Investigator: Terry L. Bowlin
Award Amount: $2,200,524.00
Abstract:
DESCRIPTION (provided by applicant): Cytomegalovirus (CMV) infection represents a major health concern in the immunocompromised population, especially recipients of bone marrow and solid-organ transplants. The current standard for therapy is ganciclovir (G CV), and its prodrug valGCV, both of which… More

Bacterial DnaA Initiator Protein: A Target for Novel Antibiotics

Award Year / Program / Phase: 2008 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $293,875.00
Abstract:
DESCRIPTION (provided by applicant): We intend to develop new chemical classes of antibacterials by focusing on an under-exploited target in a well- validated pathway. Specifically, we will develop and apply a high-throughput screen for inhibitors of the E scherichia coli DnaA protein, an essential… More

Identification of Novel Broad Spectrum Influenza Virus Inhibitors

Award Year / Program / Phase: 2008 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $489,188.00
Abstract:
DESCRIPTION (provided by applicant): Broad-spectrum therapeutics against influenza virus infections are critically needed to address the problem of influenza pandemics, a major threat to the public health globally. Interfering with virus entry is a novel a nd attractive therapeutic strategy to… More

Antibiotic Potentiators Targeting SOS Induction

Award Year / Program / Phase: 2008 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $600,000.00
Abstract:
DESCRIPTION (provided by applicant): Several clinically important classes of antibiotics strongly induce the SOS response in bacteria. SOS defective bacteria are significantly more sensitive to quinolone, fluoroquinolone, and 2-lactam antibiotics than are wild type bacteria. Induction of the SOS… More

Therapeutics targeting fatty acid synthesis in P. aeruginosa

Award Year / Program / Phase: 2008 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $592,209.00
Abstract:
DESCRIPTION (provided by applicant): Pseudomonas aeruginosa is a common and extremely virulent cause of serious infections in immune- compromised/suppressed patients (e.g., HIV and cancer), cystic fibrosis patients, and those on mechanical ventilation or w ith burn wounds. Frequent antibiotic… More

Inhibitors of the Y. pestis cell surface plasminogen activator for biodefense

Award Year / Program / Phase: 2009 / SBIR / Phase I
Agency: HHS
Principal Investigator: Marjorie H. Barnes
Award Amount: $562,071.00
Abstract:
DESCRIPTION (provided by applicant): Yersinia pestis is a Gram-negative bacillus, which is the etiological agent of plague. Human infection by this pathogen may occur by subcutaneous (e.g., flea bite), intranasal, or intravenous routes, resulting in buboni c or pneumonic plague or septicemia,… More

Carbocyclic nucleosides as therapeutics for Ebola infections

Award Year / Program / Phase: 2009 / SBIR / Phase I
Agency: HHS
Principal Investigator: Norton P. Peet
Award Amount: $599,158.00
Abstract:
DESCRIPTION (provided by applicant): The Ebola virus (EBOV) is a Category A bioterrorism threat for which no vaccines or small- molecule therapeutics are known. EBOV is very virulent and can cause up to 90% mortality in infected individuals. Few small mole cules have been studied for their activity… More

Novel Antibacterials Targeting Gram-negative Nonfermenters

Award Year / Program / Phase: 2009 / SBIR / Phase I
Agency: HHS
Principal Investigator: Michelle M. Butler
Award Amount: $520,550.00
Abstract:
DESCRIPTION (provided by applicant): The overall objective of this project is to develop a novel chemical class of broad-spectrum therapeutic agents, the bis-(indole) lead series, for use against Gram-negative nonfermenters. The limited number and efficacy of current therapies, the scarcity of… More

Novel Methylenecyclopropane Analogues as Anti-Human Herpesvirus 6 and 8 Agents

Award Year / Program / Phase: 2009 / SBIR / Phase I
Agency: HHS
Principal Investigator: Terry L. Bowlin
Award Amount: $633,573.00
Abstract:
DESCRIPTION (provided by applicant): There is a high need for new agents that are effective and safe for treating betaherpesvirus and gammaherpesvirus related emerging infections. A new series of purine nucleoside analogs, the methylenecyclopropanes (MP), have been shown to be promising antiviral… More

Structure-Based Design of Sortase Inhibitors for Anti-Infective Therapy

Award Year / Program / Phase: 2010 / SBIR / Phase I
Agency: HHS
Principal Investigator: Bing Li
Award Amount: $599,999.00
Abstract:
DESCRIPTION (provided by applicant): The emergence of drug-resistant bacteria is an increasing health problem. Because of the resistance challenge, novel approaches which will not be subject to existing resistance mechanisms, are required for antimicrobial drug discovery. Targeting bacterial… More

A NOVEL BIS-INDOLE COMPOUND AGAINST CATHETER COLONIZATION

Award Year / Program / Phase: 2011 / STTR / Phase I
Agency: HHS
Research Institution: BAYLOR MEDICAL COLLEGE
Principal Investigator: Timothy J. Opperman – 508-757-2800
Award Amount: $599,998.00
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): Infections associated with medical devices can be serious and even fatal. Catheter colonization and production of a biofilm on the surface of a catheter shortly after implantation are normally the prelude for infections. A number of antimicrobial-treated… More

Type III Secretion Inhibitors for Anti-Infective Therapy

Award Year / Program / Phase: 2011 / SBIR / Phase II
Agency: HHS
Principal Investigator: Donald T. Moir – 508-757-2800
Award Amount: $3,000,000.00
Abstract:
DESCRIPTION (provided by applicant): Pseudomonas aeruginosa infection is the leading cause of hospital-acquired pneumonia in patients undergoing mechanical ventilation. Current antibiotic treatments exhibit failure rates as high as 18%, even when the organism is susceptible to the antibiotic being… More

Quinoline-based Inhibitors of BoNT/A LC

Award Year / Program / Phase: 2011 / SBIR / Phase I
Agency: HHS
Principal Investigator: John D. Williams – 508-757-2800
Award Amount: $599,718.00
Abstract:
DESCRIPTION (provided by applicant): The botulinum neurotoxins (BoNTs) are the most poisonous biological substances known. The lethal intravenous dose of BoNT serotype A (BoNT/A) in humans is 1-5 ng/kg. If accidental exposure to BoNT occurs (e.g., from contaminated foodstuffs), loss of life or… More

Identification of Novel Broad Spectrum Influenza Virus Inhibitors

Award Year / Program / Phase: 2012 / SBIR / Phase II
Agency: HHS
Principal Investigator: Arnab Basu – 508-757-2800
Award Amount: $2,945,791.00
Abstract:
DESCRIPTION (provided by applicant): Our goal is to develop small molecule inhibitors that target influenza entry. In Phase I, we identified several compounds that selectively inhibit the hemagglutinin (HA) mediated virus entry process. Three HA specific entry inhibitors (MBX494, MBX994, and MBX726)… More

Novel Methylenecyclopropane Analogues as Anti-Human Herpesvirus 6 and 8 Agents

Award Year / Program / Phase: 2012 / SBIR / Phase II
Agency: HHS
Principal Investigator: Terry L. Bowlin – 508-757-2800
Award Amount: $2,990,305.00
Abstract:
DESCRIPTION (provided by applicant): The human herpesviridae family contains eight members divided into three subfamilies, designated alpha, beta and gamma. The alpha herpes viruses include herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2) and varicella zoster virus (VZV). The… More

Inhibitors of S. aureus bNOS for adjunctive therapy

Award Year / Program / Phase: 2012 / SBIR / Phase I
Agency: HHS
Principal Investigator: Donald T. Moir – 508-757-2800
Award Amount: $581,000.00
Abstract:
DESCRIPTION (provided by applicant): Staphylococcus aureus is a major cause of community and hospital-acquired infections of the skin, soft tissue, and bloodstream. The recent dramatic increase in occurrence of strains resistant to beta-lactam antibiotics(MRSA) has reduced therapeutic options… More

Inhibitors of wall teichoic acid biosynthesis of Staphylococcus aureus

Award Year / Program / Phase: 2012 / SBIR / Phase I
Agency: HHS
Principal Investigator: Timothy J. Opperman – 508-757-2800
Award Amount: $595,399.00
Abstract:
DESCRIPTION (provided by applicant): The increasing prevalence of multidrug resistant infections caused by Gram-positive pathogens, such as methicillin resistant Staphylococcus aureus (MRSA), underscores the clinical need for novel strategies to treat life-threatening infections. New antibacterial… More

Novel Spectinamide Antibiotics for the Treatment of MDR/XDR Tuberculosis

Award Year / Program / Phase: 2012 / SBIR / Phase I
Agency: HHS
Principal Investigator: Michelle M. Butler – 508-757-2800
Award Amount: $585,233.00
Abstract:
DESCRIPTION (provided by applicant): The overall objective of this project is to further develop a novel chemical class of tuberculosis (TB) therapeutic agents, the spectinamide series, for use against MDR and XDR strains of Mycobacterium tuberculosis (Mtb) and identify, through a series of in vitro… More

Optimization of novel pyranopyridine efflux pump inhibitors

Award Year / Program / Phase: 2012 / SBIR / Phase I
Agency: HHS
Principal Investigator: Son T. Nguyen – 508-757-2800
Award Amount: $565,338.00
Abstract:
DESCRIPTION (provided by applicant): Infections caused by multi-drug resistance (MDR) Gram-negative pathogens are becoming increasingly difficult to treat, resulting in increased frequency of treatment failure and mortality. The increasing prevalence of MDR Gram-negative pathogens presents an… More

Novel Plasmodial Surface Anion Channel Inhibitors as Antimalarial Drugs

Award Year / Program / Phase: 2012 / SBIR / Phase I
Agency: HHS
Principal Investigator: Michelle M. Butler – 508-757-2800
Award Amount: $596,288.00
Abstract:
DESCRIPTION (provided by applicant): The overall objective of this project is to generate new, potent, selective antimalarials that act through a novel mechanism of blocking the plasmodial surface anion channel (PSAC), a previously unexploited and highly conserved plasmodial target. Human malaria is… More

Novel aryl-rhodanine inhibitors of Streptococcus mutans biofilms

Award Year / Program / Phase: 2012 / SBIR / Phase I
Agency: HHS
Principal Investigator: Timothy J. Opperman – 508-757-2800
Award Amount: $168,214.00
Abstract:
DESCRIPTION (provided by applicant): Dental caries, commonly known as tooth decay, is a serious health problem all over the world, and is one of the most common infectious diseases in humans. Dental plaque, a biofilm community growing on the tooth surface,can harbor organisms that cause dental… More

Aminoglycoside potentiators for P. aeruginosa therapy

Award Year / Program / Phase: 2013 / SBIR / Phase I
Agency: HHS
Principal Investigator: Donald T. Moir – 508-757-2800
Award Amount: $600,000.00
Abstract:
DESCRIPTION: Pseudomonas aeruginosa is a common cause of serious infections in patients with immune deficiency (e.g., HIV and cancer), cystic fibrosis (CF), on mechanical ventilation or with burn wounds. While P. aeruginosa exhibits an alarming variety ofintrinsic drug resistances, aminoglycosides… More

Medical Images, HTML5, and Clinical Trial Remote Collaboration

Award Year / Program / Phase: 2013 / SBIR / Phase I
Agency: HHS
Principal Investigator: Donald T. Moir – 508-757-2800
Award Amount: $600,000.00
Abstract:
DESCRIPTION: Pseudomonas aeruginosa is a common and extremely virulent cause of serious infections in immune- compromised/suppressed patients (e.g., HIV and cancer), cystic fibrosis patients, and those on mechanical ventilation or with burn wounds. Related clinically important Gram-negative [Gr(-)]… More